Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KCNA2 | P16389 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.44 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.43 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28424356 | 0.86 | LMNA (0.55) | LMNAGAAMAOBPOLBMAOA | |
| SCHEMBL16374957 | 0.84 | LMNA (0.63) | LMNAGAAMAOBPOLBMAOA | |
| SCHEMBL7000379 | 0.84 | LMNA (0.63) | LMNAGAAMAOBPOLBMAOA | |
| SCHEMBL6197659 | 0.84 | LMNA (0.59) | LMNAGAAMAOBPOLBMAOA | |
| SCHEMBL16345760 | 0.83 | LMNA (0.65) | LMNAGAAMAOBPOLBMAOA | |
| SCHEMBL12397417 | 0.82 | LMNA (0.60) | LMNAGAAMAOBPOLBMAOA | |
| SCHEMBL28892111 | 0.82 | LMNA (0.57) | LMNAGAAMAOBPOLBMAOA | |
| SCHEMBL6196494 | 0.82 | LMNA (0.60) | LMNAGAAMAOBPOLBMAOA | |
| SCHEMBL21627180 | 0.81 | LMNA (0.55) | LMNAGAAMAOBPOLBMAOA | |
| SCHEMBL6196940 | 0.80 | LMNA (0.54) | LMNAGAAMAOBPOLBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2692724-B1 | CHIRAL 3-HYDROXYPYRID-4-ONE DERIVATIVE, AND SYNTHESIS AND USE THEREOF | UNIV ZHEJIANG (CN) | 2016-03-16 | — | — | EP | disclosed |
| EP-2692724-A1 | CHIRAL 3-HYDROXYPYRID-4-ONE DERIVATIVE, AND SYNTHESIS AND USE THEREOF | Zhejiang University (CN) | 2014-02-05 | — | — | EP | disclosed |
| US-6506911-B2 | Reacting a 2-(1-hydroxyalkyl)-3-hydroxypyran-4(1H)one compound with benzaldehyde dimethyl acetal to form 8-oxo-4,8-dihydro-2-phenyl-4h(3,2-d)-m-dioxin, reacting it with an amine compound to form an intermediate, then reducing | BTG INTERNATIONAL LIMITED (GB) | 2003-01-14 | — | — | US | disclosed |
| EP-0984934-B1 | NOVEL ORALLY ACTIVE IRON (III) CHELATORS | BTG INTERNAT LTD COMPANY NO 26 (GB) | 2003-01-08 | — | — | EP | disclosed |
| US-6448273-B1 | SUCH AS 2,6-DIMETHOXYMETHYL-1-METHYL-3-BENZYLOXPYRIDIN-4(1H)-ONE; TREATING DISORDERS ASSOCIATED WITH IRON DISTRIBUTION AND IRON DEPENDANT PARASITES; REDUCED LEVELS OF ACTIVE AGENT; SELECTIVE TARGETING TO TISSUES AND LIVER; METABOLIC STABILITY | BTG INTERNATIONAL LIMITED (GB) | 2002-09-10 | — | — | US | disclosed |
| US-20020068758-A1 | Novel orally active iron (III) chelators | BTG INTERNATIONAL LIMITED. | 2002-06-06 | — | — | US | disclosed |
| US-6335353-B1 | 3-HYDROXYPYRIDIN-4-ONE DERIVATIVE; IRON DEFICIENCY ANEMIA AND THALASSEMIA TREATMENT | BTG INTERNATIONAL LIMITED (GB) | 2002-01-01 | — | — | US | disclosed |
| EP-0984934-A1 | NOVEL ORALLY ACTIVE IRON (III) CHELATORS | BTG INTERNATIONAL LIMITED (Company No. 2664412) (GB) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998054138-A1 | NOVEL ORALLY ACTIVE IRON (III) CHELATORS | BTG INTERNATIONAL LIMITED (GB) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068758-A1 | Novel orally active iron (III) chelators | HAMP, HRH2, GRHPR | LMNA 2634/4885GAA 1367/4885MAOB 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.